Todd Billeci has been an active photographer in the San Francisco Bay Area since the mid-1980s, primarily focused on black and white street photography, avant-garde music, and performance art. Todd studied fine art film photography with Jerry Ott (Ansel Adams Institute) and currently works in digital media. Todd’s current project, Docile Bodies, examines the relationship between technology and the body—and technocracy and dehumanization in general—realized as conceptual still life and nude studies. Todd is also an accomplished cellist and pianist, performing throughout the Bay Area as a member of the Contemporary Chamber Players specializing in 20th century classical music; Todd won second place at an international music competition in Vienna as well as numerous concerto competitions. Todd is a research pharmaceutical chemist, with multiple biotechnology patents and numerous peer-reviewed publications and book chapters. Over the decades, he has held positions as scientific director (Science & Medicine) and medical director (Helix), was a research fellow at Genentech, Inc., and has been a board member of numerous scientific organizations.
Recent Photo  work​​​​​​​

2018

Album Cover, XII, Vlimmer (Berlin)
Blackjack Illuminist Records
Release: Nov. 22, 2018

Liner Notes Art, albums XI and XII, Vlimmer (Berlin)
Blackjack Illuminist Records
Release: Nov. 22, 2018

Experimental Short Film, Nuit
Collaboration with Silo Portem (Scotland, U.K.)
Release: Edinburgh Festival of Sound, Nov. 17 2018

Promotional Advert
Blackjack Illuminist Records
Release: Nov. 15, 2018

Album Cover [collaborative], Otzi (Oakland)
Part-Time Punks Sessions
KXLU Los Angeles
Release: Oct. 17, 2018

2017

San Francisco Pride, 2017 (poster)
Seattle Psych Festival, 2017 (advert)
Portland Psych Festival, 2017 (advert)

Recent Group Exhibitions
2016 King City, 10 September–1 October, Gallery Automatic, Belmont, CA.
PATENTS

Genentech, Inc. October 09, 2003
The present invention provides novel solution phase hybridization-based methods for detecting and quantitating nucleic acid analytes. Methods comprising use of novel capture polymers and/or signaling systems are provided. Use of these novel capture polymers and/or signaling systems provides significant improvements in ...

Genentech, Inc. September 02, 2004
The present invention provides novel solution phase hybridization-based methods for detecting and quantitating nucleic acid analytes. Methods comprising use of novel capture polymers and/or signaling systems are provided. Use of these novel capture polymers and/or signaling systems provides significant improvements in ...

Genentech, Inc. October 09, 2003
L'invention porte sur de nouveaux procédés à base d'hybridation de détection et quantification d'analytes d'acides nucléiques en phase soluble comprenant l'utilisation de nouveaux polymères de capture et/ou systèmes de signalisation. L'utilisation de ces nouveaux polymères apporte une am...

Genentech, Inc. January 15, 2004
The present invention provides novel solution phase hybridization-based methods for detecting and quantitating nucleic acid analytes. Methods comprising use of novel capture polymers and/or signaling systems are provided. Use of these novel capture polymers and/or signaling systems provides significant improvements in ...

Genentech, Inc. June 28, 2006
The present invention provides novel solution phase hybridization-based methods for detecting and quantitating nucleic acid analytes. Methods comprising use of novel capture polymers and/or signaling systems are provided. Use of these novel capture polymers and/or signaling systems provides significant improvements in ...

Genentech, Inc. January 12, 2005
L'invention porte sur de nouveaux procédés à base d'hybridation de détection et quantification d'analytes d'acides nucléiques en phase soluble comprenant l'utilisation de nouveaux polymères de capture et/ou systèmes de signalisation. L'utilisation de ces nouveaux polymères apporte une am...

RESEARCH PUBLICATIONS
Journal Articles and Book Chapters

1. Billeci TM and Stults JT: Tryptic mapping of recombinant proteins by matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 13:1709-16, 1993.

2. Henzel WJ, Billeci TM, Stults, JT, Wong SC, Grimley C and Watanabe C: Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 90:5011-5015, 1993.

3. Henzel WJ, Grimley C, Bourell JH., Billeci TM., Wong S and Stults JT: Analysis of two-dimensional gel proteins by mass spectrometry and microsequencing. Methods: Companion Methods Enzymol 6:239-247, 1994.

4. Henzel WJ, Billeci TM, Stults JT, Wong S, Grimley C and Watanabe C: Identifying proteins at the femtomole level by molecular mass searching of peptide fragments in a protein sequence database. In Techniques in Protein Chemistry, Vol. V, J. W. Crabb Ed., Academic Press, New York, 1994, pp 3-9.

5. Lukavsky P, Billeci TM, James TL and Schmitz U:  NMR structure determination of a 28-nucleotide RNA from the mammalian signal recognition particle, In Molecular Modeling of Nucleic Acids, J SantaLucia and NB Leontis Eds, ACS, Washington, DC, 1998, pp 122-149.

6. Mujeeb A, Ulyanov NB, Billeci TM, Farr-Jones S and James TL: Conformational ensemble calculations: analysis of protein and nucleic acid NMR data. In Modern Techniques in Protein NMR, LJBN RamaKrishna Ed, Plenum Press, 1998.

7. Furrer P, Billeci TM, Donati A, Kojima C, Karwowski B, Sierzchala A, Stec W and James TL:  Structural effect of complete [Rp]-phosphorothioate and phosphorodithioate substitutions in the DNA strand of a model antisense inhibitor-target RNA complex. J Mol Biol 285:1609-1622, 1999.

8. Mujeeb A, Clever JL, Billeci TM, James TL and Parslow TG: Structure of the dimer initiation complex of the HIV-1 genomic RNA, Nature Struct Biol 5:432-436, 1998.

9. Tonelli M, Ulyanov NB, Billeci TM, Karwowski B, Guga P, Stec WJ and James TL: Dynamic NMR structures of [Rp]- and [Sp]-phosphorothioated DNA-RNA hybrids, Biophysical Journal 85:2525-2538, 2003.


Abstracts

1. Billeci TM., Henzel WJ, Wong S, Grimley C, Watanabe C and Stults JT: Identifying proteins from two-dimensional gels at the femtomole level. Western Pharmaceutical and Pharmacological Sciences Meeting, San Francisco, CA, 1993.

2. Henzel WJ, Billeci TM, Stults JT, Wong S, Grimley C and Watanabe C: A novel approach for identifying two-dimensional gel proteins by molecular mass searching of peptide fragments in protein sequence databases. 7th Symposium Protein Society, San Diego, CA, 1993.

3. Gillece-Castro B, Guzetta A, Billeci TM, and O'Connell K.: Electrospray ionization mass spectrometry of glycopeptides and oligosaccharides. 5th Sanibel Conference on Mass Spectrometry: Mass Spectrometry of Carbohydrates, Sanibel Island, FL, 1993.

4. Stults JT, Billeci TM, Henzel WJ, Wong S, Grimley C and Watanabe C: Carbohydrate-containing matrices for MALDI: applications to recombinant protein digests and in situ digests of proteins from two-dimensional gels. 41st ASMS Conference on Mass Spectrometry and Allied Topics, San Francisco, CA, 1993.

5. Kealey JT, Gu XR., Billeci TM and Santi DV: Mechanism of m5U54 tRNA methyltransferase. American Society for Biochemistry and Molecular Biology Annual Meeting, San Francisco, CA, 1995.

6. Schmitz U, Billeci TM, Vinayak R, Feymann DM, Keenan R, Walter P and James T: NMR Studies of the conserved RNA domain of mammalian signal recognition particle. 37th Experimental NMR Conference, Asilomar, CA, 1996.

7. Schmitz U, Billeci TM, James TL and Lukavsky P: NMR studies of the conserved 43-nucleotide RNA domain of mammalian signal recognition particle. 213th American Chemical Society National Meeting, San Francisco, CA, 1997.

8. Lukavsky P, Behrens S, Billeci TM, James TL and Schmitz U: NMR studies of the conserved 43- nucleotide RNA domain of mammalian signal recognition particle. 10th Conversation in Biomolecular Stereodynamics, Albany, NY, 1997.

9. Billeci TM, Furrer P, Donati A, Kojima C, Stec W and James TL: Phosphorothioate and phosphorodithioate modifications of antisense oligomers: A structural comparison.10th Conversation in Biomolecular Stereodynamics, Albany, NY, 1997.

10. Lukavsky P, Billeci TM, James TL and Schmitz U: Structure of the RNA domain of signal recognition particle. 2nd Itl. RNA Conference, Santa Cruz, CA, 1998.

11. Billeci TM, Furrer P, Donati A, Kojima C, Stec W and James TL: Solution structures of phosphorothioate and phosphorodithioate-containing antisense agents. ACS/FASEB, San Francisco, CA, 1998.

12. Billeci TM, Furrer P, Donati A, Kojima C, Stec W, and James TL: Antisense agent–target RNA complexes at high resolution. UCSF Asilomar Conference, Asilomar, CA, 1999.


MEDICAL PUBLICATIONS

1. Derby R, Lee SH, Chen Y: Injection therapies, nerve ablation and IDET for degenerative lumbar conditions. Seminars in Spine Surgery, in press.

2. Traina TA, Rugo H, Caravelli J, Yeh B, Panageas K, Bruckner J, Norton L, Park J, Hudis C, Dickler M: Letrazole with bevacizumab is feasible in patients with hormone-receptor–positive metastatic breast cancer. J Clin Oncol, submitted.

3. Perez EA, Hillman DW, Kugler JW, Steen PD, Fitch TR, Rowland KM: North central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizuman as first-line chemotherapy for patients with metastatic breast cancer. J Clin Oncol, submitted.

4. Jahanzeb M: Evolution of bevacizumab therapy for the treatment of breast cancer. Clin Breast Cancer, submitted.

5. Mahtani RL, Macdonald JS: Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 13:39-50, 2008.

6. Overman MJ, Hoff PM: EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum 50:1259-70, 2007.

7. Perez-Soler R, Van Cutsem E: Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology 21:10-16, 2007.

8. Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA: Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 25:632-46, 2007.

9. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V: A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 5:61, 2007.

10. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-21, 2006.

11. Diasio RB and Fourie J: Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 66:1441-63, 2006.

12. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Lüss H, Meyer M: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27:2823-32, 2006.

13. Fruehauf J: EGFR function and detection in cancer therapy. J Exp Ther Oncol 5:231-46, 2006.

14. Perez-Soler, R: Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8 Suppl 1:S7-14.

15. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J, Hevezi P, Cass KM, Watson S, Evangelista F, Powers RA, Finck B, Wills M, Caras I, Fang Y, McDonald D, Johnson D, Murray R, Jeffry U: Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5:273-86, 2006.

16. Tan BR, McLeod HL: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol. 32:113-9, 2005.

17. Venook, AP: Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 103:1-12, 2005.

18. Kumar PS and Pegram M: Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 16:483-494, 2005.

19. Derby R, Kim B-J, Lee S-H, Chen Y, Seo K-S, Aprill C: Comparison of discographic findings in asymptomatic subject discs and the negative control discs of chronic LBP patients: can discography distinguish asymptomatic discs among morphologically abnormal discs? Spine J 5:389-94, 2005.

20. Derby R, Chen Y, Lee S-H, Seo KS, Kim B-J: Non-surgical interventional treatment of cervical & thoracic radiculopathies. Pain Physician 7:389-94, 2005.

21. Derby R, Kim BJ: Effect of intradiscal electrothermal treatment with a short heating catheter and fibrin on discogenic low back pain. American J Physical Med Rehabilitation 84:560-61, 2005.

22. Derby R, Lettice JJ, Kula TA, Lee SH, Seo KS, Kim BJ: Single-level lumbar fusion in chronic discogenic low back pain: psychological and social status as a predictor of outcome using the 36-item short form. J Neurosurg Spine 3:255-61, 2005.

23. Ellis LM: Epidermal growth factor receptor in tumor angiogenesis. Hematology/Oncology Clin North America 18:1007-1021, 2004.

24. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocrin Relat Cancer 11:689-708, 2004.

25. Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treatment Reviews 30:1-17, 2004.

26. Lee SH, Derby R, Chen Y, Kim MJ, Seo KS: In vitro measurement of pressure in the intervertebral discs and annulus fibrosus with and without annular tears during discography. Spine J 4:614-8, 2004.

27. Derby R, Guyer R, Lee SH: Current issues of IDET. ISIS Newsletter 6:15-18, 2004.

28. Derby R, Eek B, Kim BJ, Lee SH: Comparison of intradiscal restorative injections and intradiscal electrothermal treatment (IDET) in the treatment of low back pain. Pain Physician. 7:63-6, 2004.

29. Derby R, Lee SH, Seo KS, Kazala K, Kim BJ, Kim MJ: Efficacy of IDET for relief of leg pain associated with discogenic low back pain. Pain Pract 4:281-5, 2004.

30. Chen Y, Derby R, Lee SH: Percutaneous disc decompression in the management of chronic low back pain. Orthopedic Clin North Am 35;17-23, 2004.

31. Chen Y, Derby R, Kim BJ, Lee SH: Epidural steroid injection—past, present & future. SpineLine 9:17, 2003.

32. O’Neill CW, Kurgansky M E, Derby R, Ryan DP: Disc stimulation and patterns of referred pain. Spine 27:2776-81, 2002.

Developed Abstracts

1. Kozloff M, Sugrue MM, Berlin J, Flynn PJ, Kabbinavar F, Sargent D, Purdie DM, Dong W, Grothey, A: Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRiTE prospective cohort study. ASCO GI, 2008 #454.

2. Sugrue MM, Purdie DM, Flynn PJ, Grothey A, Sargent DJ, Berlin J, Kabbinavar F, Dong W,  Kozloff M: Serious wound healing complications in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRiTE observational cohort study. ASCO GI, 2008 #450.

3. Flynn PJ, Sugrue MM, Purdie DM, Grothey A, Sargent D, Berlin J, Kabbinavar F, Dong W, Kozloff, M: Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRiTE observational cohort study. ASCO GI, 2008 #346.

4. Lenz HJ, Mayer RJ, Gold P, Mirtsching B, Stella PJ, Cohn A, Pippas AW, Malloy P, Azarnia N, Needle M, Van Cutsem E: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplain. ASCO 2005 #3510.

5. Lenz HJ, Mayer R, Gold P, Mitsching B, Cohn AL, Pippas AW, Azarria N, Windt P, Van Cutsem E: Activity of cetuximab in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin. ACSO GI, 2005 #10269.

6. Bonner J, Harari P, Giralt J, Baselga J, Shin DM, Cohen R, Jassem J, Azarnia N, Molby P, Ang K: Improved preservation of larynx with the addition of cetuximab for cancers of the larynx and hypopharynx. ASCO 2005 #5530.

7. Pippas AW, Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Van Cutsem E: Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. ASCO 2005 #3595.

8. Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas AW, Ding C, Van Cutsem E: Consistent response to treatment with cetuximab monotherapy with metastatic colorectal cancer. ASCO 2005 #3536.

9. Van Cutsem E, Mayer RJ, Gold P, Stella PJ, Cohn A., Pippas AW, Windt P, Malloy P, Lenz HJ: Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. EORTC-NCI-AACR 2004 #279.

10. Cosler LE, Homberger J, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph node-negative, estrogen receptor-positive, early stage breast cancer. ASCO 2004.

11. Habel LA, Quesenberry CP, Jacobs MK, Blick NT, Greenberg D, Alexander C, Baker J, Walker M., Watson D, Hackett J, Shak SA: Large case-control study of gene expression and breast cancer death in the northern california Kaiser Permanente population. ASCO 2004.

12. Lyman GH, Cosler L, Homberger J: A 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer: an age-specific economic analysis. ASCO 2004.

13. Paik S, Shak S, Tang G, Kim C, Kim W, Baker J, Cronin M, Walker M, Watson D, Bryant J and Wolmark N: Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size, and tumor grade. ASCO 2004.


14. Derby R, Chen Y, Seo KS, Kim B-J, Lee S-H: Lumbar disc annular disruption in the determination of discogenic pain sources. 3rd Congress of the World Institute of Pain (WIP), Barcelona, Spain, September 21-25, 2004.
Back to Top